Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00595101 |
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
Condition | Intervention | Phase |
---|---|---|
Primary Open Angle Glaucoma Ocular Hypertension |
Drug: PF-03187207 Drug: Latanoprost |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2, 28-Day Parallel-Group, Double-Masked, Dose Finding Study Comparing The Safety And Efficacy Of PF-03187207 To Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension. |
Estimated Enrollment: | 120 |
Study Start Date: | December 2007 |
Study Completion Date: | June 2008 |
Arms | Assigned Interventions |
---|---|
PF-03187207 High Dose: Experimental
N/A
|
Drug: PF-03187207
1 drop, once a day in each treated eye.
|
PF-03187207 Low Dose: Experimental
N/A
|
Drug: PF-03187207
1 drop, once a day in each treated eye.
|
PF-03187207 Middle Dose: Experimental
N/A
|
Drug: PF-03187207
1 drop, once a day in each treated eye.
|
Latanoprost: Active Comparator
N/A
|
Drug: Latanoprost
1 drop, once a day in each treated eye.
|
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Japan | |
Pfizer Investigational Site | |
Shizuoka, Japan | |
Japan, Chiba | |
Pfizer Investigational Site | |
Narashino, Chiba, Japan | |
Pfizer Investigational Site | |
Inbagun Suimachi, Chiba, Japan | |
Japan, Kanagawa | |
Pfizer Investigational Site | |
Kawasaki, Kanagawa, Japan | |
Japan, Saitama | |
Pfizer Investigational Site | |
Kasukabe, Saitama, Japan | |
Japan, Shizuoka | |
Pfizer Investigational Site | |
Susono, Shizuoka, Japan | |
Pfizer Investigational Site | |
Fuji, Shizuoka, Japan | |
Pfizer Investigational Site | |
Mishima, Shizuoka, Japan | |
Japan, Tokyo | |
Pfizer Investigational Site | |
Hachioji, Tokyo, Japan | |
Pfizer Investigational Site | |
Hamura, Tokyo, Japan | |
Pfizer Investigational Site | |
Minato, Tokyo, Japan | |
Pfizer Investigational Site | |
Musashino, Tokyo, Japan | |
Pfizer Investigational Site | |
Setagaya, Tokyo, Japan |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A9441003 |
Study First Received: | January 4, 2008 |
Last Updated: | July 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00595101 |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Glaucoma Eye Diseases Glaucoma, Open-Angle |
Vascular Diseases Latanoprost Hypertension Ocular Hypertension |
Therapeutic Uses Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |